In addition, Plk1 is highly linked to cancer development: activated Plk1 induces a rapid loss of ciliation by binding to Dishevelled 2 (Dvl2) or by phosphorylation of nephrocystin-1 in HeLa and hTERT-RPE cell lines [46, 47], raising the question whether Plk1 inhibitors like volasertib (BI 6727) used in clinical trials are able to interfere with ciliogenesis [48]. This evidence concerns the gene NPHP1 and cancer.